SAN DIEGO, Dec. 15, 2017 /PRNewswire/ -- Johnson Fistel, LLP, is investigating potential violations of the federal securities laws by Zymeworks Inc. (NYSE : ZYME ) ("Zymeworks") and certain of its officers and directors. Zymeworks is a technology platform biotech company with a focus primarily on cancer drug development. Zymeworks develops protein therapeutics for the treatment of cancer based upon the Company's molecular modeling software for optimizing protein structure.
On April 28, 2017, Zymeworks sold 4.5 million shares of stock in its initial public stock offering (the "IPO"), raising $58.50 million in new capital. However, since the IPO, Zymeworks stock has imploded, on December 14, 2017, the stock closed at $8.13.
Specifically, Johnson Fistel's investigation seeks to determine whether the Company's filings with the U.S. Securities and Exchange Commission in connection with its April 2017 initial public stock offering (the "IPO") contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company's clinical trials, business and operations.
If you have information that could assist in this investigation, or if you are a Zymeworks shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (firstname.lastname@example.org) at 619-814-4471. If emailing, please include a phone number.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson Fistel, LLP
Jim Baker, 619-814-4471
SOURCE Johnson Fistel, LLP